Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 204

1.

PSA kinetics provide improved prediction of survival in metastatic hormone-refractory prostate cancer.

Robinson D, Sandblom G, Johansson R, Garmo H, Aus G, Hedlund PO, Varenhorst E; Scandinavian Prostate Cancer Group.

Urology. 2008 Oct;72(4):903-7. doi: 10.1016/j.urology.2008.05.026. Epub 2008 Jul 17.

PMID:
18639324
[PubMed - indexed for MEDLINE]
2.

Prognostic significance of the nadir prostate specific antigen level after hormone therapy for prostate cancer.

Kwak C, Jeong SJ, Park MS, Lee E, Lee SE.

J Urol. 2002 Sep;168(3):995-1000.

PMID:
12187207
[PubMed - indexed for MEDLINE]
3.

Prostate-cancer-specific survival and clinical progression-free survival in men with prostate cancer treated intermittently with testosterone-inactivating pharmaceuticals.

Scholz M, Lam R, Strum S, Jennrich R, Johnson H, Trilling T.

Urology. 2007 Sep;70(3):506-10.

PMID:
17905106
[PubMed - indexed for MEDLINE]
4.

Clinical outcome of maximum androgen blockade using flutamide as second-line hormonal therapy for hormone-refractory prostate cancer.

Miyake H, Hara I, Eto H.

BJU Int. 2005 Oct;96(6):791-5.

PMID:
16153202
[PubMed - indexed for MEDLINE]
5.

Failing to achieve a nadir prostate-specific antigen after combined androgen blockade: predictive factors.

Park SC, Rim JS, Choi HY, Kim CS, Hong SJ, Kim WJ, Lee SE, Song JM, Yoon JH.

Int J Urol. 2009 Aug;16(8):670-5. doi: 10.1111/j.1442-2042.2009.02329.x. Epub 2009 Jul 13.

PMID:
19602007
[PubMed - indexed for MEDLINE]
6.

Prostate-specific antigen doubling time and survival in patients with advanced metastatic prostate cancer.

Loberg RD, Fielhauer JR, Pienta BA, Dresden S, Christmas P, Kalikin LM, Olson KB, Pienta KJ.

Urology. 2003 Dec 29;62 Suppl 1:128-33. Review.

PMID:
14747050
[PubMed - indexed for MEDLINE]
7.
8.

Evaluation of prostate-specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy.

Sridhara R, Eisenberger MA, Sinibaldi VJ, Reyno LM, Egorin MJ.

J Clin Oncol. 1995 Dec;13(12):2944-53.

PMID:
8523059
[PubMed - indexed for MEDLINE]
Free Article
9.

Prediction of survival of metastatic prostate cancer based on early serial measurements of prostate specific antigen and alkaline phosphatase.

Robinson D, Sandblom G, Johansson R, Garmo H, Stattin P, Mommsen S, Varenhorst E; Scandinavian Prostate Cancer Group (SPCG)-5.

J Urol. 2008 Jan;179(1):117-22; discussion 122-3. Epub 2007 Nov 12.

PMID:
17997442
[PubMed - indexed for MEDLINE]
10.

Prostate-specific antigen response duration and risk of death for patients with hormone-refractory metastatic prostate cancer.

D'Amico AV, Chen MH, Cox MC, Dahut W, Figg WD.

Urology. 2005 Sep;66(3):571-6.

PMID:
16140080
[PubMed - indexed for MEDLINE]
11.

Flutamide versus orchidectomy in the treatment of metastatic prostate carcinoma.

Boccon-Gibod L, Fournier G, Bottet P, Marechal JM, Guiter J, Rischman P, Hubert J, Soret JY, Mangin P, Mallo C, Fraysse CE.

Eur Urol. 1997;32(4):391-5; discussion 395-6.

PMID:
9412794
[PubMed - indexed for MEDLINE]
12.

Prostate-specific antigen doubling time is associated with survival in men with hormone-refractory prostate cancer.

Semeniuk RC, Venner PM, North S.

Urology. 2006 Sep;68(3):565-9.

PMID:
17010728
[PubMed - indexed for MEDLINE]
13.

Significance of prostate-specific antigen-doubling time on survival of patients with hormone refractory prostate cancer and bone metastasis: analysis on 56 cases of cancer-specific death.

Tomioka S, Shimbo M, Amiya Y, Nakatsu H, Murakami S, Shimazaki J.

Int J Urol. 2007 Feb;14(2):123-7.

PMID:
17302568
[PubMed - indexed for MEDLINE]
14.

Survival of patients with hormone refractory prostate cancer in the prostate specific antigen era.

Oefelein MG, Agarwal PK, Resnick MI.

J Urol. 2004 Apr;171(4):1525-8.

PMID:
15017212
[PubMed - indexed for MEDLINE]
15.

Pretreatment prostate-specific antigen velocity is associated with development of distant metastases and prostate cancer mortality in men treated with radiotherapy and androgen-deprivation therapy.

Palma D, Tyldesley S, Pickles T; Prostate Cohort Outcomes Initiative.

Cancer. 2008 May 1;112(9):1941-8. doi: 10.1002/cncr.23388.

PMID:
18338814
[PubMed - indexed for MEDLINE]
Free Article
16.

Assessment of prostate-specific antigen doubling time in prediction of prostate cancer on needle biopsy.

Spurgeon SE, Mongoue-Tchokote S, Collins L, Priest R, Hsieh YC, Peters LM, Beer TM, Mori M, Garzotto M.

Urology. 2007 May;69(5):931-5.

PMID:
17482937
[PubMed - indexed for MEDLINE]
17.

Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.

Smith JA Jr, Lange PH, Janknegt RA, Abbou CC, deGery A.

J Urol. 1997 Apr;157(4):1329-34.

PMID:
9120932
[PubMed - indexed for MEDLINE]
18.

Prostate specific antigen half-time and prostate specific antigen doubling time as predictors of response to androgen deprivation therapy for metastatic prostate cancer.

Park YH, Hwang IS, Jeong CW, Kim HH, Lee SE, Kwak C.

J Urol. 2009 Jun;181(6):2520-4; discussion 2525. doi: 10.1016/j.juro.2009.01.104. Epub 2009 Apr 16.

PMID:
19371894
[PubMed - indexed for MEDLINE]
19.

Time to prostate-specific antigen nadir after androgen suppression therapy for postoperative or postradiation PSA failure and risk of prostate cancer-specific mortality.

Chung CS, Chen MH, Cullen J, McLeod D, Carroll P, D'Amico AV.

Urology. 2008 Jan;71(1):136-40. doi: 10.1016/j.urology.2007.08.028.

PMID:
18242382
[PubMed - indexed for MEDLINE]
20.

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

Hussain M, Tangen CM, Higano C, Schelhammer PF, Faulkner J, Crawford ED, Wilding G, Akdas A, Small EJ, Donnelly B, MacVicar G, Raghavan D; Southwest Oncology Group Trial 9346 (INT-0162).

J Clin Oncol. 2006 Aug 20;24(24):3984-90.

PMID:
16921051
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk